News | January 08, 2026
Lilly to buy Ventyx Biosciences for $1.2 billion
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The primary goal of the collaboration is joint research into trending and next-generation molecules
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The move strengthens GBL’s clinical-stage presence in the United States
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Subscribe To Our Newsletter & Stay Updated
